ESC 365 - The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor

ESC Professional Premium Access

The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor

Session: Antidiabetic medications and cardiovascular disease

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor C. Chen (Taipei, TW)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Chihwei Chen

Taipei Medical University Hospital, Taipei (Taiwan)

0 follower

6 more presentations in this session

Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study

Speaker: Assistant Professor Y. Chen (Taichung, TW)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus

Speaker: Professor Y. Oh (Seoul, KR)

Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

Speaker: Doctor R. Kani (Kamogawa, JP)

GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study

Speaker: Ms K. Soerensen (Copenhagen, DK)

Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc

Speaker: Professor G. Tse (Hong Kong, CN)

Access the full session

Antidiabetic medications and cardiovascular disease

Speakers: Doctor C. Chen, Assistant Professor Y. Chen, Professor Y. Oh, Doctor R. Kani, Ms K. Soerensen...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources